Metraipolis › archive › dc_6da8931383c2

Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma — Europe PMC PMID:42326932

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42326932
DOI
10.3389/fpubh.2026.1749414
License (as archived)
solo-consultazione
Archived
2026-10-31T18:28:55.042Z
SHA-256 of the archived text
372fde03540db2d4e96f0c40e4bc3f5fd1c4bbf281c20e88ac0f44efdd16c364
Stable URL of this page
https://metraipolis.com/documento/dc_6da8931383c2

How to cite

Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma — Europe PMC PMID:42326932 — Europe PMC (en), https://europepmc.org/article/MED/42326932 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6da8931383c2 (Metraipolis archive dc_6da8931383c2, sha256 372fde03540db2d4e96f0c40e4bc3f5fd1c4bbf281c20e88ac0f44efdd16c364)
BibTeX
@misc{dc6da8931383c2,
  title = {Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma — Europe PMC PMID:42326932},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42326932},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6da8931383c2; sha256 372fde03540db2d4e96f0c40e4bc3f5fd1c4bbf281c20e88ac0f44efdd16c364},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42326932. Agents can read the archived copy with the MCP tool read_document.